A randomized trial of minoxidil in chemotherapy-induced alopecia

Duvic, Madeleine; Lemak, Noreen A.; Valero, Vicente; Hymes, Sharon R.; Farmer, Kathryn L.; Hortobágyi, Gabriel N.; Trancik, Ronald J.; Bandstra, B.; Compton, Linda D.

doi:10.1016/s0190-9622(96)90500-9

Cited by 150 publications

(79 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, topical application of minoxidil was not effective in this animal model. In cancer patients, topical application of a 2% solution of minoxidil reduced the duration of CIA by an average of 50 days in a study of 22 patients undergoing adjuvant therapy for breast cancer [13], but it did not protect against alopecia induced by doxorubicin-based chemotherapy in a study of 48 women with solid tumors [43]. Immunophilin ligands, such as cyclosporin A and FK506, also promote hair growth.…”

Section: Current and Future Therapeutic Modalitiesmentioning

confidence: 99%

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Hesketh

Batchelor²,

Golant

et al. 2004

Support Care Cancer

124

View full text Add to dashboard Cite

Despite advances in the treatment of many side effects associated with chemotherapy, alopecia remains an issue that is difficult to resolve. Chemotherapy-induced alopecia (CIA) is a condition that can have profound psychosocial and quality-of-life consequences, resulting in anxiety, depression, a negative body image, lowered self-esteem, and a reduced sense of well-being. Patients who fear CIA may sometimes select regimens with less favorable outcomes or may refuse treatment. When supporting patients with CIA, health care providers should use an individualized approach with a focus placed on the actual moment of hair loss. Education, support groups, and self-care strategies are important components of any management approach. No treatment modality for preventing CIA has been clearly shown to be effective. Recent evidence suggests that new scalp hypothermic regimens may be safe and effective. There remains a critical need for effective new approaches to this problem.

show abstract

Section: Current and Future Therapeutic Modalitiesmentioning

confidence: 99%

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Hesketh

Batchelor²,

Golant

et al. 2004

Support Care Cancer

124

View full text Add to dashboard Cite

show abstract

“…So far, pharmacological attempts to reduce CIA have also been rather ineffective. Topical application of minoxidil proved ineffective in suppressing CIA; however, the time to complete hair regrowth was shortened [8,9]. Over the last years, the technique of controlled scalp cooling was developed (i.e., a constant decrease of the scalp temperature to about 7 ° C during and for a certain period after CT).…”

Section: Introductionmentioning

confidence: 99%

The Influence of Various Parameters on the Success of Sensor-Controlled Scalp Cooling in Preventing Chemotherapy-Induced Alopecia

et al. 2015

View full text Add to dashboard Cite

Background: The influence of systemic comorbidities on the success of scalp cooling during chemotherapy (CT) is widely unexplored. Comorbidities often require additional medication which itself can occasionally cause alopecia. This study investigates the influence of selected parameters on the efficacy of scalp cooling for the prevention of CT-induced alopecia. Patients and Methods: 226 cancer patients were treated with various CT regimens in combination with sensor-controlled scalp cooling. 136 breast cancer patients received (neo)adjuvant therapy, and 76 of these patients received epirubicine and cyclophosphamide (4× EC 3w) followed by paclitaxel (12× T w). The following parameters were prospectively investigated: chemotherapy-induced alopecia, systemic comorbidities and co-medication, nicotine abuse, hair treatment, menopausal status, and trichologic status. Results: Scalp cooling was successful (no or not visible hair loss; common toxicity criteria 0-1) in 65% of all patients, in 65% of the 136 breast cancer patients, and in 68% of the 76 patients receiving EC/T. In this subgroup, premenopausal patients (p = 0.009) and those without systemic comorbidities (p = 0.003), without co-medication (p < 0.001) and with high hair density (p = 0.038) showed less hair loss during CT; an effect was also seen for nicotine abuse (p = 0.023). Hair length and hair treatment had no significant influence. Conclusion: Sensor-controlled scalp cooling represents an effective addition to supportive cancer therapy. The success of scalp cooling depends on the applied CT regimen. Parameters like menopausal status, systemic comorbidities, medication, nicotine abuse, and original hair density also influence the outcome of hair loss prevention.

show abstract

“…However, topical minoxidil (2%) does not protect against CIA. In one randomized clinical trial, topical minoxidil (2%) was shown to shorten the duration of CIA in breast cancer patients receiving 5-fluorouracil, doxorubicin, and cyclophosphamide (Duvic et al, 1996). The results of this study is summarized in Table 5 Table 5.…”

Section: Minoxidilmentioning

confidence: 90%

Chemotherapy-induced alopecia

2012

An Atlas of Hair Pathology With Clinical Correlations 2E

View full text Add to dashboard Cite

A randomized trial of minoxidil in chemotherapy-induced alopecia

Cited by 150 publications

References 8 publications

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

The Influence of Various Parameters on the Success of Sensor-Controlled Scalp Cooling in Preventing Chemotherapy-Induced Alopecia

Chemotherapy-induced alopecia

Contact Info

Product

Resources

About